Aprea Therapeutics, Inc. (APRE): שולי רווח תפעולי ממכירות

Aprea Therapeutics (APRE) brings together leading oncologists, providing them with academic freedom and cutting-edge equipment for scientific discovery. This chart of operating profit margins reflects a current level of approximately -457872.80. The clinical testing stage of targeted drugs precludes operating profit due to massive R&D expenditures. Anticipation of DDR inhibitor trial results remains the primary driver while the market currently prices in these losses.
פילוחי מדדים ואנליטיקה של חברת Aprea (APRE)

This metric is calculated as the ratio of operating profit to revenue, allowing for an assessment of cost management efficiency before accounting for debt load and taxes. By analyzing the operating margin spread, an investor can see the potential of Aprea Therapeutics (APRE) to generate excess profits through the monopoly status of its innovative targeted ovarian cancer therapy, which directly impacts the fundamental value of the business.